NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

CompletedPhase 1

Sponsor: Atea Pharmaceuticals, Inc.

Conditions: Healthy Volunteer Study

Interventions: Period 1: AT-527 550 mg, Period 2: carbamazepine, Period 3: AT-527 550 mg + carbamazepine, Period 3: AT-527 1100 mg + carbamazepine

Countries: Canada

This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
* Females must have a negative pregnancy test at Screening and prior to dosing
* Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
* Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria:

* Pregnant or breastfeeding
* Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19
* Abuse of alcohol or drugs
* Use of other investigational drugs within 28 days of dosing
* Use of other prescription drugs with 28 days of dosing
* Other clinically significant medical conditions or laboratory abnormalities

Locations (1)

Montreal, Quebec, Canada